Phase 1 Test-retest Evaluation of [18F]MNI-958 PET as an Imaging Marker for Tau Protein in the Brain of Patients With Alzheimer's Disease and Probable PSP as Compared to Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 26 Mar 2019
Price : $35 *
At a glance
- Drugs 18FMNI 958 (Primary)
- Indications Alzheimer's disease; Progressive supranuclear palsy
- Focus Diagnostic use
- 19 Mar 2019 Planned End Date changed from 12 Mar 2019 to 12 Mar 2020.
- 19 Mar 2019 Planned primary completion date changed from 12 Mar 2019 to 12 Mar 2020.
- 06 Jun 2018 New trial record